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Abstract 
Background: Mild Cognitive Impairment (MCI) is a disorder in which the patient presents a cognitive decline, but without negative impact on the 
activities of daily living. Objective: To carry out a systematic review of published studies that analyzed the prevalence of Mild Cognitive Impairment (MCI) in 
older adults living in the community, and the criteria used for the diagnosis of this disorder. Methods: A search was carried out in May 2017 using the descriptors: 
“epidemiology” or “prevalence”, “mild cognitive impairment”, and “community” in the PubMed, PsycInfo, SciELO, Web of Science, and Scopus databases. Two 
independent researchers extracted and documented the data. We used a random effect model to calculate pooled prevalence of MCI for overall studies and for 
each subgroup divided by diagnostic criteria. Results: We found initially 1996 articles, and we selected 35 studies. The prevalence of MCI in the selected 
studies ranged from 0.5% to 41.8%. The overall pooled prevalence of MCI was 17.3% (CI 95%, 13.8-20.8), with significant heterogeneity between estimates (I2 
= 99.6%). Discussion: The standardization of the diagnostic criteria for MCI, as well as the tests used in the cognitive evaluation, could allow the comparison 
between the studies and would be an important step in the researches of this area.
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Introduction
Mild cognitive impairment (MCI) is the term used for the disorder 
between cognitive age changes and early stages of dementia. 
Patients with this morbidity show a decline in cognitive function 
with respect to their baseline pattern and has no negative impact on 
the activities of daily living. The aim of the diagnosis of MCI is to 
identify individuals at the onset of cognitive decline, although not 
all individuals will progress to dementia1,2.
MCI has received several denominations and definitions over 
the last 20 years, with Mayo Clinic criteria being the most accepted. 
The original Mayo MCI criteria evidenced memory impairment 
with preservation of the other cognitive domains. The criteria 
include memory loss, preferably corroborated by an informant; 
target memory impairment; general cognition preserved; preserved 
activities of daily living; and absence of dementia2. Later, research 
has expanded MCI symptomatology into other cognitive domains, 
and has considered memory impairment a condition not necessarily 
present, with the remaining criteria being better known as the 
Petersen Criteria3. Petersen criteria evidenced cognitive complaint, 
preferably corroborated by an informant; target cognitive 
impairment; general cognition preserved; preserved activities 
of daily living; and absence of dementia.
We have studies indicating a conversion of 10% to 15% 
per year of amnestic MCI in AD, for others MCI subtypes the 
conversion is still undefined, which highlights the importance 
of this disorder, since dementia is one of the diseases that most 
overburden developed countries and their health systems. 
Therefore, preventive measures are urgently needed4-6.
Despite the growing importance of MCI, studies in the area are 
still scarce, being a large part of them performed in clinical settings, 
such as reference centers for cognitive disorders, generating several 
implications. For example, depending on the admission mechanism 
of the research site, some selection criteria applied can recruit only 
individuals with etiology for this disorder, usually those with a 
degenerative origin, or with a positive family history for dementia. On 
the other hand, community-based studies, by definition, would not 
restrict the nature of the sample, but rather provide heterogeneity2,7.
Therefore, the main objective of this study is to carry out a 
systematic review of all published studies that analyzed the prevalence 
of MCI in older adults living in the community, and the criteria used 
for the diagnosis of this disorder.
Methods
A systematic review of national and international literature, 
regardless of the date of publication, on the prevalence of mild 
cognitive impairment in communities was carried out between 
May 2 and 16, 2017. For this purpose, the following keywords were 
used: epidemiology; prevalence; mild cognitive impairment; and 
community. The databases used were PubMed, PsycInfo, SciELO, 
Web of Science, and Scopus.
Inclusion criteria were studies with: a sample aged over 60 years, 
performed in communities; publication in English, Portuguese and 
Spanish; description of criteria used for diagnosis of MCI, and of the 
prevalence of MCI in the results.
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We excluded studies with specific clinical samples (stroke, acute 
myocardial infarction, etc.), which used only screening cognitive 
scales such as Mini-mental Status examination (MMSE), Montreal 
Cognitive Assessment (MoCA) or Addenbrooke’s Cognitive 
Examination-Revised (ACE-R) to determine MCI. We also excluded 
letters to the editor, book chapters and reviews, collection of abstracts, 
comments, notes, errata, theses, dissertations, and bibliographic/
systematic reviews. No time limitation was adopted.
Two independent researchers extracted and documented the 
following data: authorship; date, year and country of publication; 
study design; sample size; gender, age and schooling of participants; 
criteria used for diagnosis and prevalence of MCI. The data were 
reviewed, and any disagreement was discussed among the authors. 
We evaluated the individual quality of the articles using a tool 
for cross-sectional studies8. The tool is composed of ten items that 
evaluate the external validity, selection, and domain of response bias, 
internal validity, measurement bias, and analysis. In the end, the 
study may be classified as low risk (score 0-3), moderate risk (4-6), or 
high risk (7-9). Of the 35 articles selected, five presented a moderate 
risk of bias9-13. All other articles scored between 0 and 3 (low risk).
We used a random effect model to calculate pooled prevalence of 
MCI for overall studies and for each subgroup divided by diagnostic 
criteria. We divided the diagnostic criteria into three subgroups: 
memory complaint plus decline in cognitive test; cognitive complaint 
and decline in cognitive test; and decline in cognitive test. The 
percentage of total variation due to heterogeneity within the subgroups 
and the overall was evaluated by I2 measure. We also presented 
the prevalence with 95% exact confidence intervals for each study, 
subgroup, and overall studies. We used the Stata statistical software 
version 14.1 (metaprop_one command) to perform the meta-analyses. 
Results
A total of 1996 articles were found. After exclusion of duplicated 
articles, 783 articles remained. The abstracts of these articles were 
reviewed, after which 748 were excluded. The final sample consisted 
of 35 articles. The review flowchart is shown in Figure 1.
The prevalence of MCI in the selected studies ranged from 
0.5%14 to 41.8%15. The overall pooled prevalence of MCI was 
17.3% (CI 95%, 13.8-20.8), with significant heterogeneity 
between estimates (I2 = 99.6%).
Of the included studies, 40% were published between 2000 
and 2010, and 60% after 2010. Regarding the study design, 19 
were cross-sectional and 16 were longitudinal studies. The sample 
size ranged from 42 participants in a study in Australia11 to 10276 
participants in a study in China16. The country with the highest 
number of studies was the United States, followed by China.
We divided the studies into three subgroups according to the 
diagnostic criteria: memory complaint plus decline in cognitive 
test; cognitive complaint and decline in cognitive test; and decline 
in cognitive test. We divided the Tables 1, 2 and 3 summarized 
the selected articles.
The studies differed with respect to cut-off points used in cognitive 
tests. For example, impairment in cognitive domains, depending on 
the study, was defined as a performance on tests below 1.5 standard 
deviation or below 1 standard deviation or below the 10th percentile 
relative to a reference group or below normative references.
When stratified by diagnostic criteria, the prevalence varied 
according to the criteria used. The studies using the memory 
complaint plus cognitive decline had prevalence of 15.0% (95% CI 
10.4-19.7%; ranging from 0.5% to 32.6%). The studies have used 
only cognitive tests criteria had higher prevalence (21.6%; 95% CI 
16.5-26.6%) than those used cognitive and memory complaints 
plus decline in cognitive tests (Figure 2). There was significant 
heterogeneity between prevalence estimates in all subgroups. 
We also performed meta-analysis considering the following 
aspects: sample size (0-500; 501-1000; >1000), country per capita 
income and risk of bias. The heterogeneity of the studies remained 
high (>75%) in all subgroups analyzed.
In Figure 3, we presented a graph with the distribution of the 
studies considering the prevalence and the standard error (funnel 
plot). We can observe an asymmetric distribution of the studies, 
suggesting the presence of biases and/or even the heterogeneity of the 
studies. The publication bias is one of possible causes of asymmetry. 
Figure 1. PRISMA flowchart. Excerpted from: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(6):e1000097.
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Table 1. Characteristics of the selected studies that used cognitive complaint plus decline in cognitive tests as diagnostic criteria 
Authors Country/GNI per 
capita
Year Design Sample Sex (M) Age Schooling Criteria Prevalence
Afgin et al. 
(2012)17
Israel
(High)
Jan. 2003-
Dec. 2008
Cohort 944
(Total: 1,003)
49.40% MCI: 72.8 (±6.1)
Healthy:
70.7 (±5.5)
3 (3)
51% illiterate
CDR 0.5 32.1%
(303 subjects)
Artero et al. 
(2008)15
France
(High)
1991-2001 Cohort 6,892
(Total: 9,313)
MCI: 35%
Healthy: 
43.4%
MCI: 74.6 (±5.7)
Healthy: 73.1 (±4.9)
Low schooling:
MCI: 24.7%
Healthy: 22.5%
Lowest 
quartile
42%
(2882 subjects)
Ding et al. 
(2015)18
China
Shanghai Aging 
Study
(Middle)
Jan. 2010-
Sep. 2011
Cross-
sectional
3,141
(Total: 4,519)
46%
MCI: 44%
72.3 (±8.1) Illiterate:
Total: 4.26%
MCI: 8.48%
1.5 SD 19.1%
(601 subjects)
aMCI: 12.5% (393 
subjects)
na-MCI: 6.6% (208 
subjects)
Gao et al. 
(2014)9
USA
Indianapolis- 
Ibadan 
DementiaProjetc.
(High)
1992-2009
(Seven 
assessments)
Cohort 2,212
(Baseline: 
1,992)
35%
Healthy: 36%
MCI: 31.8%
74.3 (±6.9)
MCI: 75.3 (±7.1)
Healthy: 73.9 (±6.8)
Total:  
9.7 (±3.1)
MCI:  
8.9 (±3.1)
Healthy: 9.9 (±3)
1.5 SD 14.8%
(327 subjects)
Year 1992
Lee et al. 
(2009)19
Korea
GDEMCIS
(High)
1rst phase: 
Oct. 
2005-March 
2007
Cohort 927
(Total: 5,085)
33.7%
Healthy: 
34.5%
MCI1: 48.9%
MCI2: 18.1%
MCI3: 25.9%
72.9 (±6.9)
Healthy: 71.05 
(±6.02)
MCI1: 69.96 (±5.42)
MCI2: 73.63 (±6.31)
MCI3: 76.33 (±7.12)
5.2 Healthy: 
6.37 (±4.87) 
MCI1: 7.26  
(±4.39) MCI2: 
2.57 (±3.17) 
MCI3: 3.24  
(±4.41)
Cuttoffs 7.6%
(all types of MCI)
(384 subjects)
Ogunniyi  
et al. 
(2016)20
Nigeria (Middle) May-Oct. 
2013
Jan.-Feb. 
2014
Cohort 613 (Total: 
642)
30.3% 
Healthy: 
31.7% MCI: 
19.8%
72.9 (±8.5) Literate: 
Healthy: 33.6% 
MCI 13.5%
Cuttoffs 18.1%
(111 subjects)
SDa-MCI: 42.3%
MDa-MCI: 40.5%
SDna-MCI: 16.2%
MDna-MCI: 0.9%
Olazarán  
et al. 
(2015)12
Spain
The Vallecas 
Project
(High)
Oct. 2011-
Dec. 2013
Cohort 1,169
(Total: 2,077)
36.5% Total: 74.4 (±3.9) < Primary school 
Total: 18.6%
1.5 SD MCI: 7%
(82 subjects)
aMCI: 3.1%
naMCI: 0.1%
mixed MCI: 3.8%
Petersen  
et al. 
(2010)21
USA
The Mayo Clinic 
Study of Ageing
(High)
Oct. 2004-
July 2007
Cohort 2,050
(Total: 4,398)
MCI: 58.35% - - 1.0 SD 16%
(329 subjects)
SDa-MCI: 11.6%
MDa-MCI: 4.5%
SDna-MCI: 3.4%
MDna-MCI: 1.1%
Pilleron  
et al. 
(2015)22
Central Africa
CAR: Central 
African Republic
ROC: Republic of 
the Congo
(Low)
Nov. 2011-
Dec. 2012
Cross-
sectional
2,002
CAR: 973
ROC: 1029
CAR: 37.9%
ROC: 39.2%
CAR: 72.7 (±6.5)
ROC: 73.8 (±6.9)
Illiterate: Total: 
CAR: 69.2% 
ROC: 68.4%
Cuttoffs 6,6%
(133 subjects)
7.2(CAR)
(70 subjects)
6.1% (ROC)
(63 subjects)
Richard  
et al. 
(2013)23
USA
WHICAP
(High)
1999-2001 Cohort 2,160
(Total: 2,183)
- - - - 19.86%
(429 subjects)
51.7% aMCI
48.3% naMCI
Tiwari et al. 
(2013)24
India
(Middle)
2008-2010 Cross-
sectional
2,146
(Total: 2,324)
Total: 47.4% Total: 67.8 (±5.9) - - 4.6%
(99 subjects)
Vanoh et al. 
(2017)25
Malaysia
TUA
(Middle)
4 years long Longitudinal 1,993 Total: 50.3%
MCI: 56.5%
Total: 68.51 (±5.93)
MCI: 69.45 (±5.98)
Total:  
5.54 (±3.94)
MCI:  
4.62 (±3.18)
1.5 SD 16%
(315 subjects)
Yu et al. 
(2016)26
China
(Middle)
- Cohort 376
(Total: 480)
- Healthy: 68.3 (±4.1)
MCI: 68.6 (±4.7)
Healthy:  
8 (±4.3)
MCI:  
7.1 (±4.2)
- 17.6%
(66 subjects)
GNI: Gross National income; MCI: mild cognitive impairment; CDR: clinical dementia rating; SD: standard deviation; aMCI: amnestic mild cognitive impairment; naMCI: nonamnestic mild cognitive 
impairment; SDa-MCI: single-domain amnestic MCI; MDa-MCI: multiple-domain amnestic MCI; SDna-MCI: single-domain non-amnestic MCI; MDna-MCI: multiple-domain amnestic.
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Table 2. Characteristics of the selected studies that used memory complaint plus decline in cognitive tests as diagnostic criteria
Authors Country/
GNI per 
capita
Year Design Sample Sex (M) Age Schooling Criteria Prevalence
Choi et al. 
(2008)27
Korea 
(High)
July 2005-
Feb. 2007
Cross-
sectional
175 (Total: 
1,215)
53.2% Healthy: 2% 
MCI: 59.6%
Total: 74.3 (±16.7)
MCI: 73.82 (±4.51)
Healthy: 71.88 
(±4.17)
MCI: 
4.93(±3.27)
Healthy: 5.85 
(±4.63)
CDR 0.5 32.9%
(57 subjects)
Juarez-
Cedillo et 
al. (2012)28
Mexico
SADEM
(Middle)
Sep. 
2009-March 
2010
Cross-
sectional
3,036 
(Total: 
3,191)
42% MCI: 36.3%
Healthy: 42.6%
71.2 (±7.5)
MCI: 75.3 (±7.9)
Healthy:
70.9 (±7.3)
Total: 6.1 (±4.6)
MCI: 5.4 (±5.5)
Healthy: 6.2 
(±4.6)
1.5 SD 6.25%
(190 subjects)
SDa-MCI: 2.41%
MDa-MCI: 2.56%
SDna-MCI: 1.18%
MDna-MCI: 0.3%
Jungwirth 
et al. 
(2005)14
Austria
VITA
(High)
Start in May 
2000
Cross-
sectional
592 (Total: 
1,505)
Memory only: 50%
Only lack of memory: 
30.7%
Memory + lack of 
memory: 25.8%
Petersen: 66.7%
Memory only: 75.71 
(±0.44)
Lack of memory 
only: 75.83 (±0.46)
Memory + lack 
of memory: 75.89 
(±0.46)
Petersen: 75.3 (±0.2)
Memory only: 
10.5 (±1.9)
Lack of memory 
only: 9.5(±2)
Memory + lack 
of memory: 9.4 
(±1.6)
Petersen: 9.7 
(±2.1)
1.5 SD Memory only: 3.7%
(22 subjects)
Lack of memory only: 
14.9%
(88 Subjects)
Memory + lack of memory: 
5.2%
(31 subjects)
Petersen- MCI- amnestic: 
0.5% (3 subjects)
Katz et al. 
(2012)29
USA 
Eisntein 
Aging 
Study
(High)
1993-2004 Cohort 1,944 39.3% 78.8 (±5.42) Total: 13.5 
(±3.5)
1.5 SD 20%
(390 subjects)
aMCI: 11.6%
(226 subjects)
naMCI: 9.9%
Khedr et al. 
(2015)30
Egypt 
(Middle)
Sep. 2011-
Aug. 2013
Cross-
sectional
691 MCI: 58% MCI: 67.3 (±7.1) Illiterate: MCI: 
66%
1.5 SD 1.74% (12 subjects)
Kumar et 
al. (2005)31
Australia
PATH 60 + 
(High)
1st phase: 
2001/2002
Cohort 2,518 
(Total: 
4,378)
- - 13.72 Cuttoffs MCI: 3.7%
(93 subjects)
MND: 0,6%
(15 subjects)
Lee et al. 
(2009)32
Korea
KLoSHA
(High)
2005 Cross-
sectional
714 32.2% 71.9 (±5.7) < 6 years of 
schooling: 
Total: 50.7%
1.5 SD SMC: 27.59%
(197 subjects)
CDR 0.5: 17.9%
(aMCI: 59.9% and naMCI: 
40.1%)
Lee et al. 
(2012)33
Malaysia
(Middle)
Dec. 2008-
May 2009
Cross-
sectional
318 (Total: 
333)
40.9% 65.9 (±5.3) Total: 5.8 (±3.5) 1.5 SD MCI: 21.1%
(67 subjects)
aMCI: 15.4%
(49 subjects)
naMCI: 5.7%
Louis et al. 
(2005)34
USA
(High)
1992/1999-
2001
Cohort 2,230 
(Total: 
2,776)
32.5%
Healthy: 32%
a-MCI: 34.5%
na-MCI: 33.3%
77.2 (±6.6)
Healthy: 77 (±6.6)
a-MCI: 78.1 (±7)
na-MCI: 77.1 (±6.6)
10.3 (±4.8) 
Healthy: 10.5 
(±4.7) a-MCI: 
10.2 (±4.6) na-
MCI: 9.6 (±5)
1.5 SD 27.3% (aMCI 42% and
na MCI: 58%)
(608 subjects)
Ma et al. 
(2016)35
China 
(Middle)
Jan.-May 
2012
Cross-
sectional
5,214 
(Total: 
5,291)
43.9% Healthy: 
42.19% MCI: 40.4%
72.13 (±4.22) 6.34 (±7.26) 1.5 SD 11.33%
(574 subjects)
SDa-MCI: 4.48%
(227 subjects)
MDa-MCI: 2.09%
(106 subjects)
SDna-MCI: 4.22%
(214 subjects)
MDna-MCI: 0.53%
(27 subjects)
Purser et 
al. (2005)36
USA
EPESE
(High)
1981, 1984, 
1987, 1991
Cohort 3,673 39.7% 74 Total: 11 Cuttoffs 22%
(810 subjects)
Shimada et 
al. (2013)37
Japan
OSHPE 
(High)
2011/2012 Cross-
sectional
5,025 
(Total: 
5,104)
Healthy: 39.9%
MCI: 48.2%
- - 1.5 SD 18.8% (945 subjects)
Wang et 
al. (2015)38
China 
(Middle)
Jan. 2010-
Jan. 2011
Cross-
sectional
3,136 Total: 40.65% Total: 69.3 (±6.8) - 1.5 SD 20% (625 subjects)
GNI: Gross National income; MCI: mild cognitive impairment; CDR: clinical dementia rating; SD: standard deviation; SDa-MCI: single-domain amnestic MCI; MDa-MCI: multiple-domain amnestic 
MCI; SDna-MCI: single-domain non-amnestic MCI; MDna-MCI: multiple-domain amnestic; aMCI: amnestic mild cognitive impairment; naMCI: nonamnestic mild cognitive impairment; MND: mild 
neurocognitive disorder; SMC: subjective memory complaint.
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Table 3. Characteristics of the selected studies that used decline in cognitive tests as diagnostic criteria
Authors Country/GNI 
per capita
Year Design Sample Sex (M) Age Schooling Criteria Prevalence
César et al.
(2016)39
Brazil
(Middle)
2012 Cross-sectional 630
(Total: 738)
37%
Healthy: 34.3%
MCI: 39.3%
71.28 (±7.99)
MCI: 72.44 
(±7.72)
Healthy: 69.26 
(±7.03)
Total: 4.9 
(±4.54)
MCI: 4.23 
(±4.16)
Healthy: 
5.61(±4.83)
Cuttoffs 19.5% (135 
subjects)
Hilal et al.
(2013)40
Singapore
EDIS (High)
Aug. 2010-Feb. 
2012.
Cross-sectional 1,226 (Total: 
1,538)
- Total: 68.2 - 1.5 SD 13.3%
(164 subjects)
Mild MCI: 
6.9%
(84 subjects)
Moderate MCI:
6.5%
(80 subjects)
Hughes et al. 
(2012)41
USA
MYHAT
(High)
2006-2008 Cross-sectional 1,737
(Total: 1,982)
37.3%
Healthy: 37.7%
MCI: 37.6%
77.23 (±7.33)
MCI: 77.72 
(±7.38)
Healthy: 76.95 
(±7.29)
≤ High school:
Total: 13.24%
MCI: 12.84%
Healthy: 
13.46%
Normative 
reference
35.9%
(623 subjects)
*78: SDa-MCI
*136: MDa-
MCI *289: 
SDna-MCI 
*120: MDna-
MCI
Jager and 
Budge 
(2005)10
UK
(High)
4 year of 
study, with 3 
assessments
Cohort 157 - - - 1.5 SD 25.5% T1
(40 subjects)
Jia et al.
(2013)16
China
(Middle)
Oct. 2008-Oct. 
2009
Cross-sectional 10,276
(59.3% urban 
area and 
40.6% rural 
area)
(Total: 13,806)
(Urban: 43.2%
Rural: 41.8%)
- Illiterate:
Total:
(Urban: 17.7%
Rural: 48.2%)
1.5 SD 20.8%
(2137 subjects)
Urban: 17%
Rural: 25.1%
Low et al. 
(2004)11
Australia
(High)
- Cross-sectional 42 (Total: 127) 59.5%
Healthy: 63%
MCI: 50%
74.38 (±2.47)
Healthy: 73.3 
(±2.4)
MCI: 75.5 
(±2.2)
11.26 (±3.2) 
Healthy: 11.8 
(±3.1) MCI: 
10.3 (±3.4)
1.5 SD 11% MCI
(14 subjects)
3.14% aMCI
(4 subjects)
Paddick et al. 
(2015)42
Tanzania
(Middle)
April-Sep. 2009 Cross-sectional 296 MCI: 21.7% MCI: 82 Normative 
reference
15.5%
(46 subjects)
Saxton et al. 
(2009)43
USA
GEM
(High)
Assessments 
every 6 months
Cohort 3,063 53.8%
Healthy: 52.4%
CDR: 57.8%
NP: 54.9%
CDR+NP: 
50.6%
78.5 (±3.3)
Healthy: 78 
(±2.9)
CDR: 78.7 
(±3.4)
NP: 78.7 (±3.5)
CDR+NP: 79.6 
(±3.7)
Healthy:
14.5 (±2.8)
CDR:
13.8 (±2.8)
NP: 15 (±3.1)
1.5 SD CDR: 40.2%
(1232 subjects)
NP: 28.1%
(861 subjects)
CDR+NP: 
15.7%
(480 subjects)
Trittschuh et 
al. (2011)44
USA
ACT
(High)
2007 Cross-sectional 159 (Total: 200) 40.9% 80.2 (±6.5) 15.4 (±3.2) Factor 1:
standard vs. 
individual cut-
off points
Factor 2: 
Severity of the 
impairment 
(1vs1.5)
Factor 3: one 
vs. mean.
11.3%-91.8%
SDa-MCI:
2.5-10.7%
MDa-MCI:
1.9-61%
GNI: Gross National income; MCI: mild cognitive impairment; CDR: clinical dementia rating; SD: standard deviation; SDa-MCI: single-domain amnestic MCI; MDa-MCI: multiple-domain amnestic MCI; 
SDna-MCI: single-domain non-amnestic MCI; MDna-MCI: multiple-domain amnestic; aMCI: amnestic mild cognitive impairment; NP: neuropsychological tests.
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Heterogeneity between groups: p = 0.168
Overall  (I^2 = 99.61%, p = 0.00);
Jager et al.  (2005)
Cognitive tests
Katz et al. (2012)
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Figure 3. Distribution of the studies considering the prevalence and the 
standard error (funnel plot). 
Despite the heterogeneity found, an important feature of the 
present review was the use of community-based studies alone. In 
this type of study, shorter assessments with screening tests that 
can generate erroneous data are usually chosen. A refined clinical 
evaluation is often needed for MCI diagnosis2. Another aspect 
to be taken into account is that voluntary participation is more 
significant in community studies than those conducted in academic 
settings, such as hospitals or clinics, what facilitates the adherence 
of participants. Especially in the case of more advanced ages, which 
correspond to the MCI profile, patients who refuse to participate 
in studies likely have stronger cognitive impairment than the 
participants.45. Another limitation of the study was the non-use of 
grey literature, which could generate a publication bias.
Regarding the method for diagnosis of MCI, when only cut-off 
points in neuropsychological assessment were used to determine 
prevalence rates, without a clinical evaluation, higher values were 
found, such as the method used in the study of Trittschuch et al. 
(2016), that reported a prevalence of 91.8%. This study tested different 
cut-off points for neuropsychological tools, like standard versus 
individualized, severity of impairment (1.0 versus 1.5 SD), and level 
of impairment (any versus average).
Diagnosis based only on neuropsychological assessment does 
not consider essential criteria for MCI as clinical complaints and 
the absence of loss of functionality. It is important to emphasize 
that, although scales are useful in certain environments, they have 
several limitations and should not be equated with clinical criteria2.
The concomitant use of clinical evaluation and neuropsychological 
status resulted in lower MCI prevalence rates compared to the studies 
that used only decline in cognitive tests. However, the criterion of 
subjective cognitive complaints may be disadvantageous in studies 
not performed in selective samples of memory clinics, since a large 
percentage of individuals with memory impairments do not express 
complaints related to this and cognitive complaints may be associated 
with other pathologies, such as anxiety and depressive disorders46. 
On the other hand, subjective cognitive complaints are usually the 
only sign of incipient cognitive deterioration in people with high 
schooling who do not show impairment in cognitive performance 
if a degree of dementia occur in people with higher schooling, these 
situations are more advanced and associated with a faster cognitive 
decline than in people with low schooling5,47.
Only two studies used the Clinical Dementia Rating (CDR) value 
of 0.5 along with medical history as diagnostic criteria. CDR is a scale 
that ranges from normal (CDR 0) to questionable dementia (CDR 
0.5) and then to various stages of dementia, mild (CDR 1), moderate 
(CDR 2) and severe (CDR 3). Some studies consider CDR 0.5 as MCI; 
nevertheless, it is important to note that CDR is not a diagnostic tool, 
but rather a severity scale. Therefore, individuals with CDR 0.5 can 
meet both MCI and mild dementia criteria2.
Therefore, it is advisable that cognitive decline be assessed 
through various and objective tests rather than a single subjective 
or punctual objective assessment45. Furthermore, since the course of 
changes in normal individuals is variable and tool-dependent a good 
diagnostic anamnesis, especially in the case of pathologies such as 
MCI, is necessary along with screening tests46.
This review also highlights the importance of standardization 
for operationalization of MCI criteria, such as in what concerns 
objective cognitive impairment. Core clinical criteria for MCI (due 
to Alzheimer Disease) include cognitive impairment in one or more 
domains compared to appropriate normative data with a suggested 
deficit level of 1.0-1.5 SD below normative expectations48. If this is 
defined as a performance below 1.5 standard deviations below the 
mean of the reference group, the prevalence of MCI, from pure 
statistical reasons, will be lower than if the criterion is performance 
below 1 standard deviation. Moreover, studies with a short cognitive 
battery may fail to diagnose cases of lighter MCI due to low sensitivity, 
leading to false-negative cases5.
Although current most used criteria provide guidance on 
an operational definition of cognitive impairment in MCI, the 
literature reveals great variability in how MCI has been defined. 
Figure 2. Forest plot for prevalence of mild cognitive impairment in the 
community stratified by diagnostic criteria. 
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Discussion
The present study showed that prevalence rates of MCI in 
the community can have a large variation. Differences in the 
characteristics of the studies, such as mean age and schooling 
of the sample, diagnostic criteria, cognitive tests used, and 
operationalization of these criteria, may account for this variability.
The studies, even when divided according to the same diagnostic 
criteria used for MCI, presented high heterogeneity, precluding a 
valid prevalence. These results can vary considerably from each 
other, because of the sample definition and how the procedures are 
performed. This fact hinders a comparison between the studies, 
emphasizing the need for standardized criteria.
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Slight alterations to the operational criteria for neuropsychological 
impairment in MCI can result in anywhere from 10 to 74% of samples 
being identified as MCI49.
The criteria for MCI diagnosis should be better standardized, 
as well as their operation, to facilitate the comparability of different 
epidemiological and clinical findings. This would probably generate a 
greater stability of this disorder with the consequent identification of 
high-risk populations for developing dementia, and earlier possibility 
to onset of drug treatment. Large longitudinal studies are needed to 
document the evolution of these individuals2.
Conclusions
A total of 35 studies were selected in this systematic review. 
The prevalence of MCI ranged from 0.5% to 41.8%, with the 
overall pooled prevalence of 17.3%. This heterogeneity in the 
results may be a result of differences in the characteristics of the 
studies, such as sample age, schooling, diagnostic criteria used, 
and operationalization of these criteria. MCI diagnostic criteria 
need to be better standardized, allowing the comparison among 
the studies.
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